Bellevue Group AG
Q4 2020 13F-HR Holdings
Net value change ($000)
+1,494,681
(20.7%)
New positions
18
Sold out positions
13
Turnover %
5.2%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q3 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ARVN | 147,368 | 380.2% |
| BIIB | 135,661 | 5559.9% |
| FATE | 103,001 | 116.2% |
| IONS | 98,105 | 23.7% |
| MRNA | 71,421 | 30.2% |
| Myovant Sciences Ltd. | 61,145 | 85.5% |
| SRRK | 60,687 | 120.7% |
| CRSP | 59,885 | 75.4% |
| ALXN | 55,027 | 33.8% |
| ISRG | 51,674 | 47.5% |
Top Reduces (Value $000, Stocks/ETFs)
| MyoKardia, Inc. | -153,835 | -100.0% |
| ESPR | -69,561 | -34.2% |
| CRL | -43,768 | -55.1% |
| SGMO | -36,383 | -100.0% |
| INCY | -32,601 | -11.1% |
| MDT | -32,372 | -37.5% |
| INTERCEPT PHARMACEUTICALS, INC. | -29,031 | -99.3% |
| Livongo Health, Inc. | -28,476 | -100.0% |
| CHRS | -23,148 | -89.9% |
| HMS HOLDINGS CORP | -21,962 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|